Literature DB >> 8046478

Sublingual isosorbide dinitrate to improve technetium-99m-teboroxime perfusion defect reversibility.

G Bisi1, R Sciagrà, G M Santoro, F Zerauschek, P F Fazzini.   

Abstract

UNLABELLED: Previous studies demonstrate perfusion defect reversibility in 201Tl reinjection imaging performed after the administration of nitrates. This study tests whether the acute sublingual administration of isosorbide dinitrate (ISDN) could improve the capability of 99mTc-teboroxime to detect reversibility in exercise-induced perfusion defects.
METHODS: Ten patients with previous myocardial infarction underwent exercise, redistribution and reinjection 201Tl imaging, 99mTc-teboroxime exercise and rest scans. Following the latter, 5 mg sublingual ISDN were given, 99mTc-teboroxime was reinjected and images collected.
RESULTS: The total defect score/patient in the 201Tl images was 10.5 +/- 3.1 (mean +/- s.d.), decreasing to 7.4 +/- 2.7 after redistribution (p < 0.02) and to 4.8 +/- 2.1 after reinjection (p < 0.01 versus redistribution). The total defect score in 99mTc-teboroxime exercise images was 12.7 +/- 3.1 (p < 0.05 versus 201Tl exercise), decreasing to 7.3 +/- 3.3 at rest (p < 0.01 versus exercise, NS versus 201Tl redistribution) and to 5.6 +/- 2.6 in ISDN images (p < 0.02 versus rest, p < 0.05 versus 201Tl redistribution, NS versus reinjection). Of the 44 abnormal segments in 201Tl exercise images, the redistribution scan identified 26 defects as reversible and 18 as fixed. After reinjection, 37 defects appeared reversible and only seven fixed (p < 0.005 versus redistribution). Stress-rest 99mTc-teboroxime classified 33 segments as reversible and 11 as fixed (NS versus both 201Tl protocols). After ISDN, the uptake score increased in 19 segments. Therefore, 37 were classified as reversible and seven as fixed defects (p < 0.01 versus 201Tl redistribution, NS versus 201Tl reinjection).
CONCLUSIONS: Sublingual ISDN before 99mTc-teboroxime rest injection seemed to improve the tracer capability of detecting reversibility in exercise-induced perfusion defects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8046478

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  The quest for myocardial viability: Is there a role for nitrate-enhanced imaging?

Authors:  Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2003 Nov-Dec       Impact factor: 5.952

Review 2.  Single photon emission computed tomography perfusion imaging for assessment of myocardial viability and management of heart failure.

Authors:  Steven Burrell; Sharmila Dorbala; Marcelo F Di Carli
Journal:  Curr Cardiol Rep       Date:  2003-01       Impact factor: 2.931

3.  FDG imaging should be considered the preferred technique for accurate assessment of myocardial viability: against.

Authors:  Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

4.  Technetium 99m-labeled teboroxime: death in utero, infanticide, or failure to thrive?

Authors:  R J Burns
Journal:  J Nucl Cardiol       Date:  1995 Jan-Feb       Impact factor: 5.952

5.  Regional concordance and discordance between rest thallium 201 and sestamibi imaging for assessing tissue viability: comparison with postrevascularization functional recovery.

Authors:  P Marzullo; G Sambuceti; O Parodi; A Gimelli; E Picano; A Giorgetti; A L'Abbate
Journal:  J Nucl Cardiol       Date:  1995 Jul-Aug       Impact factor: 5.952

6.  Improved detection of myocardial perfusion reversibility by rest-nitroglycerin Tc-99m-MIBI: comparison with TI-201 reinjection.

Authors:  J F Batista; O Pereztol; J A Valdés; E Sánchez; R Stusser; L M Rochela; D López; E V Garcia
Journal:  J Nucl Cardiol       Date:  1999 Sep-Oct       Impact factor: 5.952

Review 7.  Nitrate-augmented myocardial imaging for assessment of myocardial viability.

Authors:  Z X He; M S Verani; X J Liu
Journal:  J Nucl Cardiol       Date:  1995 Jul-Aug       Impact factor: 5.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.